References
- American Cancer Society. Cancer Facts & Figures 2009. Atlanta: American Cancer Society, 2009. Available at: http://www.cancer.org/downloads/STT/500809web.pdf [Last accessed 9 June 2010]
- Hepatocellular carcinoma – United States, 2001–2006. Morbid Mortal Wkly Rep 2010;59:17:517-20
- Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society, 2007
- Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36
- Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9:1920-8
- Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
- NEXAVAR® (sorafenib) tablets, oral [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., February 2009
- Nexavar 200 mg film-coated tablets [summary of product characteristics] [prescribing information]. Berlin, Germany: Bayer Schering Pharma AG, 2010
- El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007;37(Suppl. 2):S88-S94
- El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369-80
- Sanyal A, Moyneur E, Barghout V. Comorbidities and treatment practices of patients newly diagnosed with hepatocellular carcinoma (HCC): a retrospective study [abstract]. Gastroenterology 2009;136;5(Suppl. 1):A-806
- Red Book®. Montvale, NJ: Thomson Healthcare Inc., 2007
- North Carolina State University, SAS Consulting, Department of Statistics. Available at: http://www.stat.ncsu.edu/sas [Last accessed 9 June 2010]
- Diseker R. Simplified matched case–control sampling using PROC SURVEYSELECT, SAS Users Group International (SURI) Proceedings, Paper 209-29, May 9–12, 2004, Montreal, Canada. Available at: http://www2.sas.com/proceedings/sugi29/209-29.pdf [Last accessed 9 June 2010]
- Thomas DG. Exact confidence limits for the odds ratio in a 2 × 2 table. Appl Stat 1970;20:105-10
- Rosner B. Chapter 13. Fundamental of Biostatistics, 6th edn. Pacific Grove, CA: Duxbury Press, 2005
- National Cancer Institute. SEER stat fact sheets: liver and intrahepatic bile duct. Available at: http://seer.cancer.gov/statfacts/html/livibd.html [Last accessed 9 June 2010]
- Kawada N, Imanaka K, Kawaguchi T, et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009;44(12):1190-4
- Davila JA, Morgan RO, Shaib Y, et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127:1372-80
- Ioannou GN, Splan MF, Weiss NS, et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007;5:938-45, 945
- Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105-14
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Hepatobiliary cancers. v.2.2009. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [Last accessed 9 June 2010]
- Kim WR, Gores GJ, Benson JT, et al. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology 2005;129:486-93